This bill expands the tropical disease priority review voucher program to include COVID-19 (a respiratory disease caused by a novel coronavirus), thereby providing manufacturers with incentives for development of a vaccine.
Actions
Feb 28, 2020
Referred to the House Committee on Energy and Commerce.